Loading...

GNI Group Ltd.

2160.T•JPX
HealthcareBiotechnology
$2476.00
$-10.00(-0.40%)

GNI Group Ltd. (2160.T) Stock Overview

Explore GNI Group Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-9.22%
↓ 9.22%
Profit Growth
$19.52
↓ 87.92%
EPS Growth
$19.52
↓ 88.89%
Operating Margin
2.84%
↓ 89.30%
ROE
2.78%
↓ 87.92%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 2160.TAnalyst Recommendations details for 2160.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

CEO

Dr. Ying Luo Ph.D.

Employees

867

Headquarters

Nihonbashi-Honcho YS Building, Tokyo

Founded

2007

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.